Wasfi I A, Al Ali W A, Agha B A, Kamel A M, Al Biriki N A, Al Neaimi K M
Camel Racing Laboratory, Forensic Evidence Department, Abu Dhabi, United Arab Emirates.
J Vet Pharmacol Ther. 2012 Apr;35(2):155-62. doi: 10.1111/j.1365-2885.2011.01312.x. Epub 2011 Jun 2.
The pharmacokinetics and metabolism of meloxicam was studied in camels (Camelus dromedarus) (n = 6) following intravenous (i.v.) administration of a dose of 0.6 mg·kg/body weight. The results obtained (mean ± SD) were as follows: the terminal elimination half-life (t(1/2β) ) was 40.2 ± 16.8 h and total body clearance (Cl(T) ) was 1.94 ± 0.66 mL·kg/h. The volume of distribution at steady state (V(SS)) was 92.8 ± 13.7 mL/kg. One metabolite of meloxicam was tentatively identified as methylhydroxy meloxicam. Meloxicam and metabolite were excreted unconjugated in urine. Meloxicam could be detected in plasma 10 days following i.v. administration in camels using a sensitive liquid chromatography tandem mass spectrometry (LC/MS/MS) method.
在静脉注射剂量为0.6毫克/千克体重的情况下,对6峰骆驼(单峰驼)进行了美洛昔康的药代动力学和代谢研究。得到的结果(平均值±标准差)如下:终末消除半衰期(t(1/2β))为40.2±16.8小时,全身清除率(Cl(T))为1.94±0.66毫升·千克/小时。稳态分布容积(V(SS))为92.8±13.7毫升/千克。美洛昔康的一种代谢物初步鉴定为甲基羟基美洛昔康。美洛昔康及其代谢物以未结合形式经尿液排泄。使用灵敏的液相色谱串联质谱法(LC/MS/MS),在静脉注射美洛昔康10天后仍可在骆驼血浆中检测到该药物。